US equities
|
MU
$1,071.33
▼-1.53%
NVDA
$236.67
▼-0.34%
PLTR
$201.93
▲+4.02%
SNDK
$1,653.00
▼-2.33%
META
$722.16
▲+0.12%
AMD
$639.77
▼-0.94%
INTC
$110.70
▼-2.14%
TSLA
$372.52
▼-1.40%
MU
$1,071.33
▼-1.53%
NVDA
$236.67
▼-0.34%
PLTR
$201.93
▲+4.02%
SNDK
$1,653.00
▼-2.33%
META
$722.16
▲+0.12%
AMD
$639.77
▼-0.94%
INTC
$110.70
▼-2.14%
TSLA
$372.52
▼-1.40%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Biomea Fusion, Inc. - Common Stock
(NQ:
BMEA
)
1.320
UNCHANGED
Delayed Quote
Updated: 10:23 AM EDT, Oct 8, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Biomea Fusion, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Biomea Fusion to Host Conference Call to Announce Topline Results from Phase II COVALENT-111 Study in Patients with Type 2 Diabetes (T2D)
December 16, 2024
Tuesday, December 17, 2024 at 8:00 am EST
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Oral and Poster Presentations of Icovamenib at the 22nd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)
December 12, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Preliminary Data from Ongoing COVALENT-103 Study of Investigational Covalent FLT3 Inhibitor BMF-500 in Relapsed or Refractory Acute Leukemia
December 09, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion to Host Conference Call to Present initial Clinical Data from Phase I COVALENT-103 Study of BMF-500, a Covalent FLT3 Inhibitor, in Relapsed or Refractory Acute Leukemia
December 06, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
December 02, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
November 18, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
November 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
October 30, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
October 29, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
October 21, 2024
Icovamenib is an oral covalent menin inhibitor in clinical development to investigate its impact on the function of insulin-producing beta cells
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1
October 15, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Arcadium Lithium, Norwegian Cruise Line, GitLab, Chewy And Other Big Stocks Moving Higher On Wednesday
↗
October 09, 2024
Via
Benzinga
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
October 07, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
October 01, 2024
International diabetes pioneers and thought leaders from 11 countries will work with Biomea leadership to unlock the potential of menin science and beta cell biology to advance BMF-219 and Biomea’s...
From
Biomea Fusion, Inc.
Via
GlobeNewswire
IGM Biosciences, CPI Card And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
October 01, 2024
Via
Benzinga
FDA Removes Clinical Hold On Biomea Fusion's Early-Stage Trials For Potential Diabetes Candidate
↗
September 27, 2024
FDA has lifted the clinical hold on Biomea Fusion's BMF-219 trials for type 1 and type 2 diabetes following a safety review, allowing the ongoing studies to resume.
Via
Benzinga
Nasdaq Moves Lower; Fed's Preferred Inflation Gauge Falls More Than Projected
↗
September 27, 2024
Via
Benzinga
Topics
Economy
IonQ, Biomea Fusion, Rocket Lab USA And Other Big Stocks Moving Higher On Friday
↗
September 27, 2024
Via
Benzinga
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
September 26, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
↗
September 02, 2024
Via
Benzinga
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
August 01, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
BMEA Stock Earnings: Biomea Fusion Beats EPS for Q2 2024
↗
July 31, 2024
BMEA stock results show that Biomea Fusion beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
July 31, 2024
From
Biomea Fusion, Inc.
Via
GlobeNewswire
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
July 08, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Biomea Fusion, Inc. Investors to Inquire About Securities Class Action Investigation – BMEA
July 03, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Why Ovid Therapeutics Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Monday's Mid-Day Session
↗
June 17, 2024
Via
Benzinga
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
EQNX::TICKER_START (NYSE:ATNM),(NASDAQ:SNDX),(NASDAQ:KURA),(NASDAQ:BMEA),(NYSE:JNJ) EQNX::TICKER_END
Via
FinancialNewsMedia
BMEA ANNOUNCEMENT: If You Have Suffered Losses in Biomea Fusion, Inc. (NASDAQ: BMEA), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
June 16, 2024
From
The Rosen Law Firm PA
Via
GlobeNewswire
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies
June 17, 2024
From
FN Media Group LLC
Via
GlobeNewswire
Biomea Fusion, Inc. (BMEA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
June 14, 2024
From
Bronstein, Gewirtz & Grossman, LLC
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
